Inogen (INGN) 2026 KeyBanc Capital Markets Healthcare Forum summary

Business transformation and strategic priorities

• Focused on stabilizing operations, returning to profitable growth, and expanding the innovation pipeline over the past two years.

• Transitioned from a single-product focus to a diversified portfolio across respiratory and sleep therapy, including new launches like Voxi 5 and Aurora masks.

• Targeting overlapping patient populations in home respiratory care, leveraging existing relationships with HMEs and physicians.

• Expanded total addressable market (TAM) from $400 million to $3 billion in the U.S. by entering adjacent categories.

• Building an ecosystem of connected care solutions to enhance patient outcomes and brand loyalty.

Financial performance and outlook

• Achieved 10% business growth and returned to positive adjusted EBITDA for the first time since 2021.

• Experienced order timing shifts due to customer CapEx budgets, with some Q4 orders pushed into Q1, but underlying demand remains strong.

• Guided for 6% revenue growth in 2026, with back-half weighting and meaningful contributions expected from new products.

• Focused on margin improvement through higher-margin products, cost discipline, and operational efficiencies.

• Long-term goals include achieving high single-digit revenue growth and sustained adjusted EBITDA growth over the next three to five years.

Market expansion and channel strategy

• International growth driven by deeper penetration in Europe, new markets in Latin America, and expansion plans for Asia Pacific, including China and Japan.

• B2B channel, especially HMEs, is a key growth driver, with proactive adoption of portable oxygen therapy and new products.

• Channel strategy remains flexible, aiming to ensure all patients have access to products, with ongoing evaluation for each product launch.

• Strategic partnerships with HMEs include co-development of digital connectivity and innovation to strengthen relationships.